R Akshaya, Mohan Sumithra, Vellapandian Chitra
Pharmacy/Pharmacology, Sri Ramaswamy Memorial College of Pharmacy, Sri Ramaswamy Memorial Institute of Science and Technology, Kattankulathur, IND.
Pharmacology, Sri Ramaswamy Memorial Institute of Science and Technology, Kattankulathur, IND.
Cureus. 2024 Aug 27;16(8):e67901. doi: 10.7759/cureus.67901. eCollection 2024 Aug.
A recessive X-linked illness called Duchenne muscular dystrophy (DMD) is characterized by increasing muscle weakening and degradation. It primarily affects boys and is one of the most prevalent and severe forms of muscular dystrophy. Mutations in the gene, which codes for the essential protein dystrophin, which aids in maintaining the stability of muscle cell membranes during contraction, are the cause of the illness. Dystrophin deficiency or malfunction damages muscle cells, resulting in persistent inflammation and progressive loss of muscular mass. The pathophysiology and genetic foundation of DMD are thoroughly examined in this review paper, focusing on the function of the NF-κB signaling system in the disease's progression. An important immune response regulator, NF-κB, is aberrantly activated in DMD, which exacerbates the inflammatory milieu in dystrophic muscles. Muscle injury and fibrosis are exacerbated and muscle regeneration is hampered by the pro-inflammatory cytokines and chemokines that are produced when NF-κB is persistently activated in muscle cells. The paper also examines our existing knowledge of treatment approaches meant to inhibit the progression of disease by modifying NF-κB signaling. These include new molecular techniques, gene treatments, and pharmacological inhibitors that are intended to lessen inflammation and improve muscle healing. Furthermore covered in the analysis is the significance of supportive care for DMD patients, including physical therapy and corticosteroid treatment, in symptom management and quality of life enhancement. The article seeks to provide a thorough understanding of the mechanisms causing DMD, possible therapeutic targets, and developing treatment options by combining recent research findings. This will provide clinicians and researchers involved in DMD care and research with invaluable insights.
杜兴氏肌肉营养不良症(DMD)是一种隐性X连锁疾病,其特征是肌肉逐渐衰弱和退化。它主要影响男孩,是最常见、最严重的肌肉营养不良症之一。该疾病的病因是基因发生突变,该基因编码必需的抗肌萎缩蛋白,这种蛋白在肌肉收缩时有助于维持肌肉细胞膜的稳定性。抗肌萎缩蛋白缺乏或功能异常会损害肌肉细胞,导致持续炎症和肌肉质量逐渐丧失。这篇综述文章深入研究了DMD的病理生理学和遗传基础,重点关注核因子-κB(NF-κB)信号系统在疾病进展中的作用。NF-κB是一种重要的免疫反应调节因子,在DMD中被异常激活,这加剧了营养不良肌肉中的炎症环境。当NF-κB在肌肉细胞中持续激活时产生的促炎细胞因子和趋化因子会加剧肌肉损伤和纤维化,并阻碍肌肉再生。本文还探讨了我们目前对旨在通过调节NF-κB信号来抑制疾病进展的治疗方法的认识。这些方法包括旨在减轻炎症和促进肌肉愈合的新分子技术、基因治疗和药物抑制剂。分析中还涵盖了对DMD患者支持性护理的重要性,包括物理治疗和皮质类固醇治疗,对症状管理和提高生活质量的作用。本文旨在通过结合最新研究结果,全面了解导致DMD的机制、可能的治疗靶点以及正在开发的治疗方案。这将为参与DMD护理和研究的临床医生和研究人员提供宝贵的见解。